Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research

• Status: Unknown status
• Trial end date: 2016-09-01
• Target enrollment: 0
• Participant gender: Female

Summary

While trastuzumab has been shown to prevent recurrences of breast cancer, some women may also experience damage to their heart muscle (including heart failure) as a result of their treatment. The investigators hope to learn if standard medications used in heart failure can prevent heart damage caused by trastuzumab in women with breast cancer. The investigators would also like to know if there are any ways to detect this damage earlier using magnetic resonance imaging (MRI) and blood tests.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Alberta
• Treatments: Angiotensin-Converting Enzyme Inhibitors; Bisoprolol; Perindopril

Criteria

Inclusion Criteria:

• Histologic diagnosis of HER2 positive breast carcinoma

• Eligible to receive trastuzumab

• Age > 18 years

• Able to give informed consent

• No contraindications to MRI

Exclusion Criteria:

• Known contraindication to beta-blocker therapy

• Known contraindication to ACEI therapy

• Current treatment with ACEI or beta blocker for other indication

• History of heart failure, cardiomyopathy or baseline LVEF < 50%